Reclast (Zoledronic Acid) Compassionate Use and Expanded Access

What Compassionate Use and Expanded Access Actually Mean for Zoledronic Acid

Compassionate use and expanded access are related but not identical terms. The FDA defines "expanded access" as the formal regulatory pathway allowing patients outside a clinical trial to receive an investigational drug or, in some cases, a marketed drug not yet approved for a specific indication. "Compassionate use" is a colloquial subset of that framework, typically referring to a single patient in urgent need.

For zoledronic acid specifically, the drug is already FDA-approved for postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, Paget disease of bone, and hypercalcemia of malignancy. That broad label means true expanded-access or compassionate-use requests are uncommon for this molecule. They do arise in two scenarios: pediatric patients with osteogenesis imperfecta or other rare bone diseases where no approved pediatric indication exists, and patients with off-label oncologic conditions where IV bisphosphonate data exist but label coverage does not.

The FDA Expanded Access Pathway

Under 21 CFR Part 312, Subpart I, a physician may submit a single-patient Investigational New Drug (IND) application to the FDA. For drugs like zoledronic acid that are already marketed, the manufacturer must also agree to provide the drug. Novartis or a generic manufacturer must grant a letter of authorization. The FDA typically responds to emergency IND requests within 24 hours and to non-emergency requests within 30 days. The full regulatory framework is described on the FDA expanded access guidance page.

When Pediatric Patients May Qualify

Children with osteogenesis imperfecta represent the most common real-world scenario where a clinician might pursue an IND for zoledronic acid. A 2017 Cochrane review found that bisphosphonates reduce fracture risk and increase lumbar spine bone mineral density in children with osteogenesis imperfecta, though most pediatric zoledronic acid data come from small trials rather than large phase III programs. A physician seeking this route should contact Novartis Medical Affairs or the relevant generic manufacturer's medical information line before filing the IND, since supply authorization is a prerequisite. See the Cochrane review on bisphosphonates in osteogenesis imperfecta.

The Real Approved Indications and Why They Matter for Access

Understanding the approved label shapes every downstream access conversation. If a condition is on-label, insurance coverage is more defensible, and compassionate-use arguments are unnecessary.

FDA-Approved Indications as of 2025

The current Reclast prescribing information lists these indications for the 5 mg once-yearly dose:

• Postmenopausal osteoporosis (treatment and prevention)
• Osteoporosis in men
• Glucocorticoid-induced osteoporosis in men and women expected to take systemic glucocorticoids for at least 12 months
• Paget disease of bone in men and women

A separate 4 mg formulation (Zometa) covers hypercalcemia of malignancy and multiple myeloma bone lesions. Reclast at 5 mg is not indicated for those oncologic uses. Prescribers and patients sometimes conflate the two products, which matters for prior-authorization language. The FDA label for Reclast (NDA 021223) is the authoritative document.

HORIZON Trial: The Clinical Foundation

The HORIZON Key Fracture Trial (N=7,765 postmenopausal women with osteoporosis) showed that annual zoledronic acid 5 mg IV reduced the risk of morphometric vertebral fractures by 70% at 3 years versus placebo (RR 0.30; 95% CI 0.24 to 0.38; P<0.001). Hip fracture risk fell by 41% (RR 0.59; 95% CI 0.42 to 0.83; P<0.001). These data, published in the New England Journal of Medicine in 2007, remain the clinical benchmark against which access decisions are argued with payers. NEJM 2007;356:1809 to 22.

Generic Zoledronic Acid: The Fastest Route to Lower Cost

Generic zoledronic acid is the single most impactful cost-reduction lever available to most patients. The FDA approved the first generic version in 2016 after Novartis's exclusivity period ended. Multiple manufacturers now hold ANDAs for the 5 mg/100 mL ready-to-infuse formulation.

What Generics Cost in Practice

Cash prices for generic zoledronic acid at infusion centers vary widely, but independent pharmacy and infusion-center pricing can fall between $150 and $400 per infusion in 2025, well below branded Reclast AWP. Hospital outpatient infusion departments typically bill at a chargemaster rate that is much higher, though insurer contracts and charity care bring actual out-of-pocket figures down considerably. GoodRx and similar coupon platforms cover infused medications inconsistently; the drug component may be discounted while the administration fee is separate.

Substitution Rules

Most states allow pharmacists to substitute an FDA-rated generic (AB-rated) for a branded drug without prescriber intervention unless the prescription is written "dispense as written." Because zoledronic acid is prepared and infused by a facility rather than dispensed to the patient, the substitution decision often falls on the infusion center's pharmacy director. Patients should ask explicitly: "Are you using generic zoledronic acid or branded Reclast?" The clinical outcome is identical; FDA bioequivalence standards (21 CFR 320) require AUC and Cmax within 80 to 125% of the reference listed drug.

Novartis Patient Assistance and Manufacturer Programs

Novartis operates the Novartis US Patient Assistance Foundation (NUPAF) and the Novartis Patient Assistance NOW (PAN) program. Eligibility criteria shift, so the figures below are 2025 reference points.

NUPAF Eligibility

NUPAF has historically covered US residents who lack insurance or whose insurance does not cover Reclast and whose income falls at or below 400% of the federal poverty level (roughly $60,240 for a single person in 2025, based on HHS poverty guidelines). Application is through a prescribing physician, not directly by the patient. Approval timelines average 4 to 6 weeks. Applications are available at the Novartis website or by calling 1-800-277-2254.

Using the Program in Practice: A Decision Framework

Patients and prescribers can follow this sequence to identify the lowest net cost:

1. Confirm the generic is available at the planned infusion site. If yes, ask for the cash price before billing insurance.
2. Run the insurance prior authorization. If denied, appeal with HORIZON trial data (NEJM 2007;356:1809) and current AACE/ACE osteoporosis guidelines.
3. If uninsured or underinsured, submit a NUPAF application simultaneously with the prior-authorization appeal.
4. If income exceeds NUPAF thresholds, contact the infusion facility's financial counselor about hospital charity care or sliding-scale pricing.
5. Confirm HSA/FSA payment eligibility with the benefits administrator before the infusion date.

Generic manufacturers (Mylan, Sagent, APP Pharma, and others) do not typically run individual patient-assistance programs, but large pharmacy benefit managers may have specialty-tier copay caps that apply to the drug component.

Insurance Coverage: Prior Authorization, Appeals, and Step Therapy

Most commercial plans and Medicare Part B cover zoledronic acid infusions. The coverage path differs by payer type.

Medicare Part B Coverage

Zoledronic acid infused in a physician office or outpatient hospital setting bills under Medicare Part B as a physician-administered drug. The Medicare reimbursement rate is based on the Average Sales Price (ASP) plus 6% (ASP+6%). Patients with Medicare Advantage should check their plan's specialty drug formulary. In standard Part B, the patient's 20% coinsurance after the deductible applies, which means roughly $30, $80 out-of-pocket per infusion at generic ASP rates in 2025. The Medicare Secondary Payer rules can further reduce this if a patient has supplemental coverage.

Commercial Insurance and Step Therapy

Many commercial insurers require documented failure of, or contraindication to, an oral bisphosphonate (alendronate or risedronate) before approving IV zoledronic acid. This is called step therapy. The ACE/AACE 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines state that IV bisphosphonates are appropriate for patients who "are unable to tolerate or are non-compliant with oral bisphosphonates due to GI side effects." Citing that guideline language directly in a prior-authorization appeal letter often resolves the denial. See the AACE clinical practice guidelines.

Medicaid Coverage

Coverage varies by state. All state Medicaid programs must cover FDA-approved drugs on the CMS National Drug Rebate Program list, but states may impose prior-authorization requirements. Patients on Medicaid should ask their prescriber to submit the PA with specific diagnosis codes (ICD-10 M81.0 for postmenopausal osteoporosis without fracture; M80.00 for with fracture) to reduce processing delays.

HSA and FSA Eligibility for Reclast

Zoledronic acid infusions are HSA and FSA eligible under IRS Publication 502, which classifies prescription drugs administered by medical personnel as qualified medical expenses. Both the drug cost and the infusion administration fee qualify.

Practical Steps to Pay with an HSA or FSA Card

Some infusion centers accept HSA/FSA cards directly at the point of service. Others require the patient to pay out-of-pocket and submit a reimbursement claim with an Explanation of Benefits and itemized receipt. Key documentation to retain:

• The prescriber's order showing the drug name, dose, and diagnosis
• The facility's itemized bill separating drug charge from administration charge
• The insurance EOB if any portion was billed to insurance first

The IRS does not require a letter of medical necessity for prescription drugs, but some FSA administrators do request one for infused medications. Confirming with the plan administrator before the infusion avoids delays. More detail on qualified medical expenses is in IRS Publication 502 (2024 edition).

Community Health Centers, 340B Pricing, and Safety-Net Hospitals

Patients without insurance or with high deductibles may access significantly discounted zoledronic acid through the federal 340B Drug Pricing Program.

What 340B Is

The Health Resources and Services Administration (HRSA) 340B program requires drug manufacturers to provide outpatient drugs to qualifying covered entities (federally qualified health centers, Ryan White HIV/AIDS program grantees, disproportionate-share hospitals, and others) at or below a ceiling price. For generic zoledronic acid, 340B ceiling prices can be 25 to 50% below non-340B commercial prices. Patients do not need to be uninsured to receive 340B-priced drugs; the facility captures the discount, and some pass savings directly to patients.

Finding a 340B-Covered Infusion Site

HRSA maintains a public database of covered entities at hrsa.gov. A patient can search by zip code and filter for organizations providing infusion services. Community health centers that offer infusion therapy are the most accessible option in rural or underserved areas.

Clinical Trials Offering Free Zoledronic Acid Access

Patients with conditions not covered by the current Reclast label (pediatric bone disease, atypical fracture risk assessment, certain oncologic indications) may be able to enroll in a clinical trial that provides the drug at no cost.

Searching ClinicalTrials.gov

The NIH registry at ClinicalTrials.gov lists ongoing interventional studies by condition, drug, and phase. Searching "zoledronic acid" filtered to "recruiting" status returned 143 active trials as of early 2025, spanning osteoporosis, metastatic bone disease, osteogenesis imperfecta, and glucocorticoid-related bone loss. Many Phase III and Phase IV trials cover drug cost, infusion administration, and sometimes travel reimbursement.

Patients considering trial enrollment should ask the site coordinator specifically whether:

• All infusions are provided free of charge
• Insurance is billed for any component
• Companion imaging (DEXA scans) is covered under the protocol budget

Acute Financial Hardship: Pharmaceutical Bridge Programs and NeedyMeds

When NUPAF enrollment takes 4 to 6 weeks and a patient has an urgent infusion scheduled, bridge programs and nonprofit directories can fill the gap.

The NeedyMeds database (needymeds.org) catalogs patient-assistance programs, disease-specific foundations, and state pharmaceutical assistance programs in a single searchable interface. The Patient Advocate Foundation's Co-Pay Relief Program has historically offered direct co-pay assistance for musculoskeletal conditions, though funding availability changes quarterly. The HealthWell Foundation similarly operates disease-specific funds; their bone health fund has provided co-pay relief of up to $2,000 per year for qualifying patients.

These programs typically require income documentation (last year's 1040 or two recent pay stubs), the prescriber's contact information, and an active prescription. Most can process emergency applications in 48 to 72 hours.

Safety Considerations That Affect Access Decisions

Access to zoledronic acid is not purely a financial question. Several safety parameters influence whether a patient can receive it at all, which in turn affects the site-of-care decision and cost structure.

Renal Function and Dosing Eligibility

Zoledronic acid is contraindicated in patients with creatinine clearance below 35 mL/min. The HORIZON trial excluded patients with serum creatinine above 2.0 mg/dL. A serum creatinine or estimated GFR (eGFR) check within 3 months of infusion is standard practice. Patients with CKD stage 3b or worse should have a nephrology consultation before proceeding. This renal exclusion means some patients who seek expanded access for compassionate-use reasons are ineligible on pharmacokinetic grounds regardless of the access pathway. FDA label, Section 2.4.

Acute Phase Reaction

Approximately 32% of patients receiving their first zoledronic acid infusion experience a post-dose acute phase reaction (fever, myalgia, flu-like symptoms) within 72 hours. Premedication with acetaminophen 1,000 mg before infusion and every 6 hours for 72 hours reduces this risk. Patients should schedule infusions when they can rest for 1 to 2 days, which has logistical implications for outpatient versus home infusion planning.

Osteonecrosis of the Jaw and Atypical Femur Fracture

The American Society for Bone and Mineral Research (ASBMR) task force defines bisphosphonate-related osteonecrosis of the jaw (BRONJ) and atypical subtrochanteric femur fracture as rare but recognized adverse effects. For osteoporosis dosing (annual 5 mg), the absolute risk of atypical femur fracture is estimated at 3.2 to 50 per 100,000 person-years, rising with duration of use beyond 5 years. The FDA updated the Reclast label in 2022 to include language on drug holidays after 3 to 5 years of therapy, consistent with ASBMR task force guidance.